Platelet News and Research

RSS
Three researchers recognised for their contributions to Australian medical research

Three researchers recognised for their contributions to Australian medical research

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Study may lead to new insights on use of aspirin in GI cancer

Study may lead to new insights on use of aspirin in GI cancer

New research examines complications related to labor anesthesia in women with thrombocytopenia

New research examines complications related to labor anesthesia in women with thrombocytopenia

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

Researchers develop 3D bone marrow that produces functional human platelets ex vivo

Researchers develop 3D bone marrow that produces functional human platelets ex vivo

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

PRESTIGE study suggests novel target to prevent stent thrombosis

PRESTIGE study suggests novel target to prevent stent thrombosis

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Baseline HBsAg, platelet count predict spontaneous HBsAg seroclearance

Baseline HBsAg, platelet count predict spontaneous HBsAg seroclearance

New Penn study questions relevance of fish oil-derived SPMs and their anti-inflammatory effects in humans

New Penn study questions relevance of fish oil-derived SPMs and their anti-inflammatory effects in humans

RepliCel Life Sciences announces final design specifications for next-generation dermal injector

RepliCel Life Sciences announces final design specifications for next-generation dermal injector

New study may help identify novel ways to treat immune thrombocytopenia

New study may help identify novel ways to treat immune thrombocytopenia

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.